BIOMAT Database Logo BIOMAT Database Logo

Complement activation and release of tumour necrosis factor alpha, interleukin-2, interleukin-6 and soluble tumour necrosis factor and interleukin-2 receptors during and after cardiopulmonary bypass in children. 1995

K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Department of Cardiovascular Surgery, Rikshospitalet, University of Oslo, Norway.

C3 activation products, terminal complement complex (TCC), and cytokines including interleukins 6 and 2 (IL-6, IL-2) and tumour necrosis factor-alpha (TNF), and the soluble IL-2 and TNF receptors were determined serially during and up to 48 h after open heart surgery in children. Significant increases were noted in soluble TNF and IL-2 receptor levels postoperatively (p < 0.05). No significant increase over preoperative levels was seen in the cytokines, except for IL-6 which was significantly increased postoperatively (p < 0.01), reaching a maximum 2 h postoperatively. C3 activation products and TCC levels increased significantly after weaning from cardiopulmonary bypass (p < 0.05). The IL-6 response lagged behind the complement activation. We found a significant correlation between duration of cardiopulmonary bypass and IL-6 levels 48 h postoperatively (r = 0.852, p < 0.05). We conclude that the concentration of complement activation products, IL-6 and the soluble TNF and IL-2 receptors are significantly increased after open heart surgery in children. The cytokine receptor response probably reflects some sort of regulatory mechanism.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008297 Male Males
D002315 Cardiopulmonary Bypass Diversion of the flow of blood from the entrance of the right atrium directly to the aorta (or femoral artery) via an oxygenator thus bypassing both the heart and lungs. Heart-Lung Bypass,Bypass, Cardiopulmonary,Bypass, Heart-Lung,Bypasses, Cardiopulmonary,Bypasses, Heart-Lung,Cardiopulmonary Bypasses,Heart Lung Bypass,Heart-Lung Bypasses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D004731 Endotoxins Toxins closely associated with the living cytoplasm or cell wall of certain microorganisms, which do not readily diffuse into the culture medium, but are released upon lysis of the cells. Endotoxin
D005260 Female Females

Related Publications

K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Interleukin-6 and tumour necrosis factor during cardiopulmonary bypass.
September 1994, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Aortobifemoral surgery induces complement activation and release of interleukin-6 but not tumour necrosis factor-alpha.
August 1996, Cardiovascular surgery (London, England),
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
A comparative study of release of interleukin-6 and tumour necrosis factor during normothermic and hypothermic cardiopulmonary bypass.
January 2002, Annals of cardiac anaesthesia,
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Complement activation and release of interleukin-6 and tumour necrosis factor-alpha in drained and systemic blood after major orthopaedic surgery.
February 1998, The European journal of surgery = Acta chirurgica,
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia.
October 1995, British journal of obstetrics and gynaecology,
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Interleukin-6, tumour necrosis factor and soluble tumour necrosis factor receptors in women with pre-eclampsia.
January 1995, British journal of obstetrics and gynaecology,
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.
December 1992, British journal of cancer,
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Soluble receptors to tumour necrosis factor and interleukin-6 in urine during acute pyelonephritis.
November 1997, Acta paediatrica (Oslo, Norway : 1992),
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin-6 in serum in granulocytopenic patients with fever.
April 1995, British journal of haematology,
K Saatvedt, and H Lindberg, and O R Geiran, and S Michelsen, and A O Aasen, and T Pedersen, and T E Mollnes
Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections.
January 1994, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
Copied contents to your clipboard!